Showing results (171-180 of 261) with videos related to
Sort By:
Pageof 27
Journal of Cutaneous Medicine and Surgery|February 9, 2008
Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-upJ Barrie Ross, Laura A Finlayson, P Jennifer Klotz, et al.Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 3, 2022
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearanceK Reich, K B Gordon, B Strober, et al.Advances in Therapy|May 19, 2026
Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic DermatitisRichard G Langley, Guy Gherardi, Anna Coleman, et al.The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.Journal of Drugs in Dermatology : JDD|October 12, 2019
Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Rosemary deShazo, Razieh Soltani-Arabshahi, Shalini Krishnasamy, et al.The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.European Journal of Immunology|June 1, 1992
Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfectionD W Dunne, A E Butterworth, A J Fulford, et al.Pediatric Dermatology|September 30, 2005
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label studyDoris Staab, David Pariser, Alice B Gottlieb, et al.Journal of Cutaneous Medicine and Surgery|March 26, 2009
ISA247: quality of life results from a phase II, randomized, placebo-controlled studyAditya K Gupta, Richard G Langley, Charles Lynde, et al.Pageof 27